There are a wide variety of tumour-associated chromosomal abnormalities in B and T cell malignancies which involve, on one chromosome, either an immunoglobulin or T cell receptor gene and, on the other chromosome, a putative oncogene, presumably activated by the abberration, and thus involved in the pathogenesis of the tumour cell carrying the abnormality. Although some of these abnormalities involve cellular counterparts of known v-oncogenes, e.g. the c-myc proto-oncogene at the site of chromosome translocation in Burkitt's B-cell lymphoma, more frequently the gene or region of DNA identified on the second involved chromosome location is not related to any retrovirally-encoded transduced oncogene. Why should the majority of lymphoid-specific chromosome abnormalities not involve oncogenes which naturally occur in transforming retroviruses? A possible explanation is that these newly identified loci carry differentiation stage-specific genes whose capability for involvement in tumorigenesis is restricted to a narrow time window of expression in ontogeny. In this model, the propensity for creation of chromosomal abnormalities via the rearranging genes (i.e. Ig and TCR) would merely circumvent the developmental switching of these genes by causing inappropriate gene expression. Such violations in expression patterns may involve abnormalities of lymphoid stage-specific genes or perhaps of tissue-specific genes not normally expressed in lymphoid cells. T cell tumour abnormalities involving chromosomes 10, 11 and 14 are discussed, with reference to these issues.
The Bcl-2 proto-oncogene in neoplasia S.J. Korsmeyer, T Clonal rearrangements of antigen genes (ARGs) provide useful markers in the evaluation of tissue biopsy specimens for lymphocytic malignancy. These markers are usually analysed by Southern blot hybridisation of biopsy tissue DNA using probes for immunoglobulin or T cell receptor (TCR) genes. Clonal cells composing malignant processes generally carry uniform rearrangements of these genes, which can be detected as bands in non-germline positions within Southern blot autoradiograms. In contrast, benign processes contain cells with diverse re-arrangements of ARGs, none of which is individually sufficiently abundant to be detected as a band in the autoradiogram. In addition to providing valuable information about the clonality (and, indirectly, about the malignancy) of tissues, ARG rearrangements have been used to determine the B-or T-lineage of lymphoid tumours and to identify multiple B-and/or T-lineage clones or subclones within single cases of lymphoproliferative disease. The molecular analysis of the DNA, RNA and protein products which result from the reciprocal translocation resulting in the Philadelphia chromosome (Ph), (t(9;22) (q34;ql 1)) has resulted in the identification of two related but distinct forms of chimaeric BCR/ABL protein, known as p210 and p190. Whereas the p210 encoded form of the Ph-translocation is associated with both acute leukaemias of various haematopoetic lineages and chronic myelogenous leukaemia (CML), the p190 form is associated primarily (if not exclusively) with acute forms of leukaemia.
The junctions between chromosome 22 and chromosome 9 occur within the introns of the BCR and ABL genes respectively such that the spliced mRNA product of a Ph chromosome can produce only a limited number of exon/ exon junctions despite the large variation in location of the DNA breakpoints. Analysis of RNA using the polymerase chain reaction (PCR) has confirmed the hybrid nature of the junctions encoding the BCR/ABL fusion proteins. This technique allows the rapid distinction between the p190 and p210 types of Ph-positive leukaemia. This is important, as it is still unclear what relationship exists between the acute phase of CML (or blast crisis) and de novo Ph-positive acute leukaemia. It is possible that p210 positive cases of acute leukaemia represent early transformation of CML without an overt chronic phase. Unambiguous identification of the molecular phenotypes may help to elucidate this question.
In addition, the technique is highly specific for this leukaemia specific marker and can be used in the detection of residual disease following bone marrow transplant or various other treatments. We are currently assessing its potential value in the prognosis and clinical management of Phpositive leukaemia. Adult lymphomas and leukaemias when grouped together have a crude incidence rate of over 25/100,000 per year and as such represent a substantial public health burden. The specific problems associated with studies of their epidemiology are discussed to enable interpretation of the available evidence. Then recent work is presented on the descriptive epidemiology of some of these conditions and the use of these data in producing hypotheses for testing the aetiology of the various conditions is critically reviewed.
The key risk factors are discussed and the deficiencies in our present knowledge are highlighted. Finally, possible aetiologic links between different disease groups are presented and future study directions are highlighted. Therapy in childhood using radium-224, an a-emitting Ra isotope, caused many osteosarcomas but no leukaemia. Since no osteosarcoma has been noted in a child or adult at Sellafield or Dounreay, it is unlikely that leukaemia at either site was caused by an osteotropic a-emitting radionuclide.
Recent revision of bomb dosimetry leaves unexplained the marked difference in induced CML between Hiroshima and Nagasaki. Induction of AML in bomb survivors depended markedly on exposure age, children being least sensitive.
In 80,000 irradiated cases of cervix Ca induced malignant disease was less than predicted from the bomb survivor experience. The t(14;18) translocation is considered characteristic of follicular and some cases of diffuse B-cell lymphoma and is thought significant in the pathogenesis of follicle centre cell tumours. We have augmented the cytogenetic analysis of B-cell tumours with molecular probes recognising both major and minor translocation breakpoints. Southern blotting using molecular probes has enabled the retrospective analysis of frozen biopsies from the routine files. In The t(14;18) translocation is a consistent characteristic of follicular lymphoma and has been shown to involve the juxtaposition of the bcl-2 gene into the IGH locus. It has been proposed that this event can occur as a mistake in V-D-J joining or, alternatively, through a strand scission and repair mechanism. In order to address this question, a series of bcl-2/Ig junctions on der (14) chromosomes was examined by PCR amplification and direct sequence analysis. In most patients, the bcl-2 gene was fused to a JH sequence with a short intervening region of unidentifiable sequence, usually considered to be N-region. In one patient, however, a bcl-2/ Ig junction was found which juxtaposed bcl-2 next to a DH sequence which itself had been arranged to lie next to a 6 sequence. This DH gene was identical to one previously shown to lie just 5' of a t(14;18) breakpoint. This unusual configuration supports the idea that at least some the 'N' regions found at breakpoints might represent parts of previously unknown DH regions. A PCR strategy was also devised for a similar analysis of the der (18) It can be difficult to distinguish a neoplastic, monoclonal B-cell proliferation from a polyclonal lymphoid proliferation on the basis of morphology and immunophenotype. Early in the development of the B-cell, the DNA of the immunoglobulin (Ig) heavy chain locus undergoes a series of rearrangements which result in a unique combination of variable (VH), diversity (DH), and joining (JH) segments separated by TdT inserted N-regions. It is now a relatively common practice to isolate and analyse DNA by restriction enzyme digests and hybridisation in order to determine whether clonal rearrangement of the immunoglobulin heavy chain gene is present, but this requires a relatively large specimen. We have employed the polymerase chain reaction (PCR) in order to detect the presence of monoclonal VH-DH-JH rearrangements using primers predicted from the conserved sequences of the surrounding VH and JH segments. This procedure requires I jig or less of DNA and is more rapid than the conventional Southern blot protocols. We have found that in DNA from a polyclonal lymphoid population, the amplified PCR fragments result in a 'smear' when analysed by polyacrylamide gel electrophoresis. This is probably due to the variation in length of the N-regions in addition to the variability in length of the DH segments. In contrast, in 7/11 B-cell lymphomas analysed, a discrete band is observed following PCR (Ig-PCR positive), as all tumour cells, being progeny of a single cell and having undergone a unique Ig heavy chain rearrangement, possess N and DH combination of the same sequence and length. Two out of four of the Ig-PCR negative samples and one out of seven of the Ig-PCR positive samples were rearranged in the BCL2 major breakpoint region as analysed by PCR. Regionalised variable theory (RVT) was developed to analyse spatially distributed properties that vary in a random, unpredictable manner. Early applications of its methods were in the mining industry to estimate the amount of metal/ mineral in ore deposit. The central tool of RVT is the variogram which defines the pattern and spatial scale of the variation. Once the variogram has been modelled we can use the model parameters for estimation by kriging. Kriging is an optimal estimation procedure that uses the form of the spatial variation contained in the variogram to provide the best possible estimates with known confidence. The spatial variation can then be mapped isarithmically.
We are investigating the possibility of applying kriging to the incidence of childhood cancer. The problems -we face relate to the low rates, the statistical distribution and the lack of continuity in the variation. This last problem has been faced by workers in diamond mining, yet In order to identify the immunologically reactive epitopes on the gag proteins of HTLV-1 we have synthesised overlapping peptides covering p19 and p24. We have identified an epitope near the carboxyl terminus of p19 recognised by a monoclonal antibody reactive with p19 but which also crossreacts with other tissues (Robert-Guroff et al., 1981 , J. Exp. Med., 154, 1957 . Sera from HTLV-1 seropositive patients show reactivity with two regions near the carboxyl terminus of p19.
We are investigating the epitopes recognised by HTLV-2 positive sera and those recognised by sera classified as HTLV-1 negative according to accepted criteria, which contain antibodies reactive with viral gag proteins. The results of these investigations should assist in determining the significance of cross-reactive antibodies in the sera of non HTLV-1-infected persons.
Activation of HTLV-1 and HSV-1 promoter constructs by HHV- Human herpes virus type 6 (HHV-6) is able to replicate in T cells and therefore may act as co-factor in the activation of Human T Cell Leukaemia Virus (HTLV-1). In order to study the interaction between the two viruses J Jhan cells were transfected with HTLV-1 LTR CAT constructs and infected with HHV-6. A 200-fold increase in CAT expression was observed compared to non infected controls. Time course studies showed activation of the HTLV-1 CAT construct to be due to HHV-6 proteins produced early in infection. Activation by HHV-6 and HTLV-1 tax is synergistic. In addition, an HTLV-1 CAT construct in which the 21bp repeat tax responsive sequences were deleted was still strongly induced by HHV-6 although basal levels of expression were greatly reduced showing HHV-6 and HTLV-1 tax to operate by different mechanisms. In order to determine if any basal regulatory elements are required for activation by HHV-6 a series of HSV-1 gD promoter deletion mutants are being studied. The association of human herpesvirus-6 (HHV-6) seropositivity and antibody titre with haematological malignancies was examined utilising 940 sera from a case controlled epidemiological survey.
In an indirect immunofluorescence assay 55% of the control sera were positive for HHV-6 antibody at a titre > 1:40 and there was a significant increase in geometric mean titre (GMT) in females. Analysis of individual disease subtypes showed there was a strong association between seropositivity and titre in acute myeloid leukaemia, Hodgkin's disease (HD) and low-grade non-Hodgkin's lymphoma; the GMT ratios of cases to controls being 3.97, 2.94 and 5.2 respectively (95% CI).
These results may reflect altered patterns of HHV-6 replication or reactivation in these conditions. In HD, however, there was evidence for increased titres and seropositivity in young cases that lacked siblings in the family. It is possible that late infection by HHV-6 is occurring in these cases and the immune response to HHV-6 may play a role in the pathogenesis of HD. (Evans & Gutensohn, 1984, Int. J. Cancer, 34, 149) and HHV-6 (Clark et al., submitted) in HD cases. In addition, one report has described the detection of HTLV-1 by PCR in a case of HD (Duggan et al., 1988 , Blood, 71, 1027 .
In a series of 37 cases of HD which were analysed for the presence of immunoglobulin heavy chain (IgH) and T-cell receptor (TCR) gene rearrangements, we used Southern blot analysis to look for the presence of EBV and HHV-6 DNA. PCR was used to look for the presence of HTLV-l DNA Cytotoxics affected by multidrug resistance (MDR) in vitro are major components of AML chemotherapy, but the relevance of this phenomenon to clinical resistance is unclear. Using the MTT assay this study aims to establish in AML:
(1) the range of dose-response curves to four MDR (mitozantrone, adriamycin, VP16, vincristine) and two non-MDR cytotoxics (cytosine, thioguanine); (2) to what extent in vitro sensitivity correlates with clinical response; and (3) the frequency of the MDR phenotype. Blasts purified from peripheral blood/bone marrow in 23 patients showed wide ranges of ID50s (cytotoxic concentrations giving 50% reduction in optical density (OD) after 72 h cytotoxic exposure for all six drugs. No significant difference was seen between relapsed (n = 7) and untreated (n = 16) groups. Percentage reduction in OD at cytotoxic concentrations corresponding to approximately 1/10 peak achievable plasma levels (>70% = sensitive, < 70% = resistant) Bird et al., Cancer, 1988 , 61, 1104 correctly predicted clinical response in only four of 12 samples for which relevant in vivo and in vitro data are available.
In 12 samples all six drugs were tested in the presence and absence of 6.6 tM verapamil (VER) . Four of these (two relapsed, two untreated) showed a clear increase in sensitivity to MDR drugs in the presence of VER but in none were all four drugs affected. In vitro sensitivity to non-MDR drugs was not increased by VER.
In vitro sensitivity to component drugs measured by MTT assay predicts poorly for clinical response to combination chemotherapy. VER modification of MDR drug sensitivity in vitro is seen in both untreated and relapsed AML.
